Cybin HELP 深 沪
等待开盘 11-02 09:30:00 美东时间
10.595
-0.115
-1.07%
华盛通- 最 高10.98
- 今 开10.53
- 成交量 114.57万股
- 最 低 10.4228
- 昨 收 10.71
- 总市值 7.74亿
- 52周最高 15.15
- 市盈率 静 --
- 换手率 1.57%
- 52周最低 3.76
- 委 比 36.17%
- 总股本 7306.02万
- 历史最高 122.36
- 量 比 0.97
- 振 幅 5.20%
- 历史最低 3.76
- 每 手 1
- 风险率 2.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HELP收跌1.83%，成交额852.37万美元
10月30日，HELP（HELP）收跌1.83%，报10.71美元，成交额852.37万美元，市值7.82亿美元。 行情数据 • 开盘价：10.91美元 • 最...
10-30 05:52
HELP收涨1.67%，成交额1091.35万美元
10月27日，HELP（HELP）收涨1.67%，报10.36美元，成交额1091.35万美元，市值7.57亿美元。 行情数据 • 开盘价：10.08美元 •...
10-27 05:53
美股大行评级 | 潜在涨幅109.52%！富国银行上调Helus Pharma目标价至22美元，维持"超配"评级
今日重点评级关注：富国银行：维持Helus Pharma"超配"评级，目标价从16美元升至22美元；美银证券：维持SpaceX"买入"评级，目标价从235美元升至275美元
10-23 12:30
Wells Fargo Maintains Overweight on Helus Pharma, Raises Price Target to $22
Wells Fargo analyst Benjamin Burnett maintains Helus Pharma (NASDAQ:HELP) with a Overweight and raises the price target from $16 to $22.
10-22 23:26
Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026
Helus Pharma Inc. announced progress on its lead programs HLP003 and HLP004. HLP003's Phase 3 topline data for adjunctive MDD treatment is expected in Q4 2026, with a potential FDA application in 2028. HLP004's Phase 2 study for GAD as monotherapy is set to begin in Q1 2027. The company highlighted the unmet needs in mental health and its commitment to advancing these programs toward commercialization.
10-21 20:10
HELP收跌4.52%，成交额1396.53万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:55
Cybin Inc. To Officially Change Name To Helus Pharma Inc. Effective October 1, 2026
Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), is pleased to announce the voting results for each of the matters presented at the Company’s annual and s...
09-23 05:30
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Helus Pharma announced the presentation of four posters at Psych Congress 2026, detailing findings on HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for major depressive disorder (MDD). The posters included 12-month efficacy results from a Phase 1/2a study, safety analysis, and an overview of the ongoing Phase 3 PARADIGM program. HLP003 has received Breakthrough Therapy Designation from the F...
09-21 11:30
9 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
09-19 01:35
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of Sept. 10, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices...
09-10 20:25
